Larimar Therapeutics (LRMR) Short-term Investments (2014 - 2026)

Larimar Therapeutics (LRMR) has reported Short-term Investments for 13 consecutive years, with $63.6 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Short-term Investments fell 46.09% year-over-year to $63.6 million; the trailing twelve-month figure through Jun 2026 stood at $63.6 million (down 46.09% YoY), and the FY2025 full-year result was $51.4 million, down 65.76% from the prior year.
• Short-term Investments improved to $63.6 million in Q2 2026 per LRMR's latest filing, from $51.4 million in the prior quarter.
• Across five years, Short-term Investments topped out at $193.8 million in Q2 2024 and bottomed at $9.9 million in Q2 2023.
• Historically, Short-term Investments has averaged $91.8 million across 5 years, with a median of $85.3 million in 2025.
• The sharpest annual moves came in 2023 and 2024: Short-term Investments plunged 71.93% in 2023, then soared 1861.26% in 2024.
• Over 5 years, Short-term Investments stood at $91.6 million in 2022, then sank by 34.46% to $60.0 million in 2023, then jumped by 150.22% to $150.2 million in 2024, then sank by 65.76% to $51.4 million in 2025, then increased by 23.6% to $63.6 million in 2026.
• According to Business Quant data, Short-term Investments over the past three periods registered $63.6 million, $51.4 million, and $85.3 million for Q2 2026, Q4 2025, and Q3 2025 respectively.